Loading clinical trials...
Loading clinical trials...
This study will determine the maximum tolerated dose of RO5045337 and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with hematologic neoplasms. ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hoffmann-La Roche
NCT07162038 · Hematologic Malignancies, Hematologic Neoplasms
NCT05882175 · HLH, Hemophagocytic Lymphohistiocytoses, and more
NCT03023202 · Hematologic Neoplasms, Solid Neoplasm
NCT06339541 · Solid Tumor, Hematologic Neoplasms
NCT03983850 · Graft Versus Host Disease, Hematologic Neoplasms
Duarte, California
New Brunswick, New Jersey
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions